Navigation Links
Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
Date:2/6/2008

ALACHUA, Fla., Feb. 6 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc. (Amex: TTG), a leading manufacturer of sterile biological implant products made from human (allograft) and animal (xenograft) tissue, today announced financial results for the first quarter of fiscal year 2008 ended December 31, 2007.

Highlights for the first quarter when compared to the previous year's first quarter include:

-- Total revenues increased 30%;

-- Revenues of dental products increased 27%;

-- Surgical specialty product revenues increased 73%;

-- U.S. revenues increased 30%;

-- International revenues increased 32%;

-- Excluding merger related costs, net income for the quarter would have

been $343,000 or $0.02 per fully diluted share, compared to a net

income of $361,000, or $0.02 per fully diluted share for the same

period last year.

As previously reported, on November 12, 2007, the Company entered into a merger agreement with Regeneration Technologies, Inc. The merger agreement provides that the Company's stockholders will receive 1.22 shares of Regeneration Technologies common stock for each share of the Company's stock that they own. Upon completion of the merger, the Company's stockholders will own approximately 45% of the combined company, on a fully diluted basis. The proposed merger is currently estimated to be completed later this month.

For the first quarter of fiscal year 2008, the Company reported revenues of $15.0 million compared to $11.5 million in the first quarter of the previous year; an increase of 30%. The gross margin for the first quarter was 54%, up from 50% in the fourth quarter. The first quarter gross margin of 54% was less than the g
'/>"/>

SOURCE Tutogen Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
6. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... 11 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( ... M. Gomez has joined Biomoda as a Senior,Research ... its,assay for the early detection of lung cancer., ... associate research scientist at,Lovelace Respiratory Research Institute in ...
... (Nasdaq: BCRX ) today announced Thomas J. ... interim Chief Medical Officer. Dr.,Simon brings more than ... his position at BioCryst., (Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO ... have Tom join BioCryst at this important time,",said ...
... Treatments have,commenced on the new Elekta Synergy(R) S ... a world-leading provider of intra- and,extracranial stereotactic radiosurgery., ... 30, 2007 with a colon,cancer treatment followed by ... patients treated with Elekta Synergy S are spine ...
Cached Biology Technology:Biomoda Hires Senior Scientist to Expand Research & Development Effort 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 4Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC 2Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC 3
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, ... Children,s Hospital Boston. Findings were published online on June ... Because it is nontoxic and can be taken orally, ... preventive therapy for patients at high risk for cancer ...
... -- Clinician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center are ... in the care of patients with traumatic brain injury ... be given nutritional supplementation through a gastric feeding tube ... their chances of survival by as much as four-fold. ...
... day, a staggering number of cells perform a feat that ... perfect replicas of each other. The process is called mitosis, ... hallmarks of cancer. Little is known about ... Fox Chase Cancer Center and Technion-Israel Institute of Technology in ...
Cached Biology News:New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 2New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 3Following traumatic brain injury, balanced nutrition saves lives 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 3
cystatin A (N-18)...
Human Cystatin A MAb (Clone 224705)...
...
... Ultra low freezers , Ultima ... critical material storage, Ultima II represents the ... in general purpose and blood bank configurations, ... IntrLogic microprocessor control system with built-in voltage ...
Biology Products: